# Genta Incorporated clinical trials: 27 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 27 trials with Genta Incorporated as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genta Incorporated: 27 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/genta-incorporated

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 27
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 27, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 31, 2012 | NCT01609127 | Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer | Genta Incorporated | Phase 2 | Unknown | Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01609127) |
| April 9, 2012 | NCT01573468 | Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer | Genta Incorporated | Phase 2 | Unknown | Gastric Carcinoma | 580 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01573468) |
| May 5, 2011 | NCT01348009 | Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer | Genta Incorporated | Phase 1/2 | Unknown | Gastric Carcinoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01348009) |
| April 18, 2011 | NCT01337310 | Study of Tesetaxel in Japanese Patients With Solid Tumors | Genta Incorporated | Phase 1 | Unknown | Advanced Solid Tumors | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01337310) |
| March 15, 2011 | NCT01315431 | A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors | Genta Incorporated | Phase 1 | Unknown | Solid Tumor | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01315431) |
| February 15, 2011 | NCT01296243 | Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer | Genta Incorporated | Phase 2 | Unknown | Prostate Cancer | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01296243) |
| October 15, 2010 | NCT01221870 | Tesetaxel as First-line Therapy for Metastatic Breast Cancer | Genta Incorporated | Phase 2 | Unknown | Breast Neoplasm | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01221870) |
| October 7, 2010 | NCT01215877 | Tesetaxel for Previously Treated Patients With Bladder Cancer | Genta Incorporated | Phase 2 | Unknown | Carcinoma, Transitional Cell | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01215877) |
| July 28, 2010 | NCT01170975 | Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules | Genta Incorporated | Phase 1 | Completed | Solid Tumors | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01170975) |
| March 29, 2010 | NCT01095120 | Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer | Genta Incorporated | Phase 2 | Unknown | Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01095120) |
| March 25, 2010 | NCT01092585 | Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH | Genta Incorporated | Phase 2 | Unknown | Melanoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01092585) |
| March 14, 2008 | NCT00636545 | Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors | Genta Incorporated | Phase 1 | Completed | Solid Tumors | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00636545) |
| October 12, 2007 | NCT00543231 | A Phase I Study of G3139 Subcutaneous in Solid Tumors | Genta Incorporated | Phase 1 | Completed | Tumors | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00543231) |
| October 12, 2007 | NCT00543205 | Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic... | Genta Incorporated | Phase 2/3 | Terminated | Advanced Melanoma and Normal or Impaired, Hepatic Function | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00543205) |
| October 12, 2007 | NCT00543075 | Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal... | Genta Incorporated | Phase 1 | Completed | Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00543075) |
| October 12, 2007 | NCT00542893 | A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine | Genta Incorporated | Phase 1 | Completed | Advanced Melanoma | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00542893) |
| August 21, 2007 | NCT00518895 | Trial of Dacarbazine With or Without Genasense in Advanced Melanoma | Genta Incorporated | Phase 3 | Completed | Melanoma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00518895) |
| August 16, 2007 | NCT00517218 | This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination... | Genta Incorporated | Phase 3 | Withdrawn | Lymphocytic Leukemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00517218) |
| December 8, 2006 | NCT00409383 | Abraxane and Temodar Plus Genasense in Advanced Melanoma | Genta Incorporated | Phase 1 | Unknown | Melanoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00409383) |
| February 23, 2004 | NCT00078234 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | Genta Incorporated | Phase 1/2 | Completed | Chronic Lymphocytic Leukemia | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00078234) |
| February 13, 2003 | NCT00054808 | Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma | Genta Incorporated | Phase 2 | Completed | Non-Hodgkin's Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Low-Grade Lymphoma, Intermediate-Grade Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00054808) |
| January 27, 2003 | NCT00030641 | Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer | Genta Incorporated | Phase 2/3 | Unknown | Lung Cancer | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00030641) |
| January 27, 2003 | NCT00024440 | Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Genta Incorporated | Phase 3 | Completed | Leukemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00024440) |
| January 27, 2003 | NCT00017602 | Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma | Genta Incorporated | Phase 3 | Completed | Multiple Myeloma and Plasma Cell Neoplasm | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00017602) |
| January 27, 2003 | NCT00017589 | Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | Genta Incorporated | Phase 2 | Completed | Leukemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00017589) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 8 |
| Phase 1/2 | 3 |
| Phase 2 | 9 |
| Phase 2/3 | 2 |
| Phase 3 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 13 |
| Unknown | 12 |
| Terminated | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Melanoma | 4 |
| Leukemia | 4 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 |
| Neoplasms | 3 |
| Stomach Neoplasms | 2 |
| Breast Neoplasms | 2 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Carcinoma, Transitional Cell | 1 |
| Urinary Bladder Neoplasms | 1 |
| Lung Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Skin Neoplasms | 1 |
| Prostatic Neoplasms | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Multiple Myeloma | 1 |
| Neoplasms, Plasma Cell | 1 |
| Leukemia, Lymphoid | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Lymphoma | 1 |
| Recurrence | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bankruptcy law firms in the United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/united-states)
- [Food and beverage distributors in the United States](https://specstream.ai/data/businesses/food-and-beverage-distributors/united-states)
- [Paper mills in the United States](https://specstream.ai/data/businesses/paper-mills/united-states)
- [Walk-in clinics in the United States](https://specstream.ai/data/businesses/walk-in-clinics/united-states)
- [Contractors in the United States](https://specstream.ai/data/businesses/contractors/united-states)
- [Israeli restaurants in the United States](https://specstream.ai/data/businesses/israeli-restaurants/united-states)
